Key result
Beta1-adrenoceptor autoantibodies from hepatitis myocarditis prolong action potentials and increase L-type Ca2+ currents up to ~56%.
Why the study?
The effects of autoantibodies against beta(1)-adrenoceptor in hepatitis virus myocarditis on action potential and L-type Ca2+ currents were not well understood.
Autoantibodies against beta1-adrenoceptor from patients with hepatitis virus myocarditis prolong action potential duration and enhance L-type Ca2+ currents, potentially contributing to arrhythmias and myocardial impairment.
May implicate β1-adrenoceptor autoantibodies in viral myocarditis arrhythmogenesis; hypothesis-generating from animal data and requires human validation.
AIM: To investigate the effects of autoantibodies against beta(1)-adrenoceptor in hepatitis virus myocarditis on action potential and L-type Ca(2+) currents. METHODS: Fifteen samples of autoantibodies against beta(1)-adrenoceptor positive sera of patients with hepatitis virus myocarditis were obtained and IgGs were purified by octanoic acid extraction. Binding of autoantibodies against beta(1)-adrenoceptor to guinea pig cardiac myocytes was examined by immunofluorescence. Using the patch clamp technique, the effects on the action potential and I(Ca-L) of guinea pig cardiac myocytes caused by autoantibodies against beta(1)-adrenoceptor in the absence and presence of metoprolol were investigated. Cell toxicity was examined by observing cell morphology and permeability of cardiac myocytes to trypan blue. RESULTS: The specific binding of autoantibodies against beta(1)-adrenoceptor to guinea pig cardiomyocytes was observed. Autoantibodies against beta(1)-adrenoceptor diluted at 1:80 prolonged APD(20), APD(50) and APD(90) by 39.2%, 29.1% and 15.2% respectively, and only by 7.2%, 5.3% and 4.1% correspondingly in the presence of 1 micromol/L metoprolol. Autoantibodies against beta(1)-adrenoceptor diluted at 1:80, 1:100 and 1:120 significantly increased the I(Ca-L) peak current amplitude at 0 mV by 55.87+/-4.39%, 46.33+/-5.01% and 29.29+/-4.97% in a concentration-dependent manner. In contrast, after blocking of beta(1)-adrenoceptors (1 micromol/L metoprolol), autoantibodies against beta(1)-adrenoceptor diluted at 1:80 induced a slight increase of I(Ca-L) peak amplitude only by 6.81+/-1.61%. A large number of cardiac myocytes exposed to high concentrations of autoantibodies against beta(1)-adrenoceptor (1:80 and 1:100) were turned into rounded cells highly permeable to trypan blue. CONCLUSION: Autoantibodies against beta(1)-adrenoceptor may result in arrhythmias and/or impairment of myocardiums in HVM, which would be mediated by the enhancement of I(Ca-L).
No takes yet. Share an insight, caveat, or question.
Liu et al. (2004) studied Hepatitis virus myocarditis (n=15). Autoantibodies against beta1-adrenoceptor vs. Presence of 1 micromol/L metoprolol was evaluated on Action potential duration and L-type Ca2+ currents. Autoantibodies against beta1-adrenoceptor from hepatitis virus myocarditis patients prolonged action potential duration and increased L-type Ca2+ peak current amplitude by up to 55.87%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: